Literature DB >> 9690657

Prostate innervation.

K T McVary1, K E McKenna, C Lee.   

Abstract

The growth of the prostate gland has been considered to be controlled exclusively by endocrine means. The abundance of alpha adrenergic and muscarinic receptors and nerve fibers suggests that the autonomic nervous system may in fact play a role in the growth maturation and secretory functions of the prostate. The predominant adrenergic input to the prostate is from short adrenergic neurons, while cholinergic nerves are closely related to the glandular epithelium, presumably affecting a secretory function. The prostate has a high density of alpha-1 and beta-2 adrenergic receptors, and the presence of these receptors, as well as their regulation by androgens, suggests and supports the direct mitogenic effect of catecholamines on prostate growth. The activated signal transduction pathways in these neural systems also appear to modulate prostatic function and growth. Denervation of the prostate results in a loss of functional and structural integrity of the gland. The effects of sympathectomy and parasympathectomy support the conclusion that the dichotomy of function in prostatic autonomic innervation has a fundamental regulatory purpose. The majority of the afferent innervation to the ventral prostate is localized to sensory nerves from the L5 and L6 segments. There is some smaller degree of innervation from T13-L2. There is evidence of extensive bilateral innervation of pelvic viscera. Despite the importance of afferent sensory feedback in regulating the control of prostate growth, its effect is of a smaller magnitude than that observed with androgens. Regardless of the specific control mechanisms suggested by neural involvement in the growth differentiation and secretory function of the prostate, the presence of innervation appears to be consistent and reproducible, and holds great potential for increasing our understanding of pathologic influences in prostate disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690657

Source DB:  PubMed          Journal:  Prostate Suppl        ISSN: 1050-5881


  27 in total

1.  Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells.

Authors:  V Sydorenko; Y Shuba; S Thebault; M Roudbaraki; G Lepage; N Prevarskaya; R Skryma
Journal:  J Physiol       Date:  2003-05-01       Impact factor: 5.182

2.  Biologic correlates and significance of axonogenesis in prostate cancer.

Authors:  Adriana Olar; Dandan He; Diego Florentin; Yi Ding; Gustavo Ayala
Journal:  Hum Pathol       Date:  2014-02-28       Impact factor: 3.466

Review 3.  Neuronal Activity in Ontogeny and Oncology.

Authors:  Humsa Venkatesh; Michelle Monje
Journal:  Trends Cancer       Date:  2017-02-13

Review 4.  Tumour innervation and neurosignalling in prostate cancer.

Authors:  Brayden March; Sam Faulkner; Phillip Jobling; Allison Steigler; Alison Blatt; Jim Denham; Hubert Hondermarck
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

Review 5.  Management of bladder, prostatic and pelvic floor disorders.

Authors:  G Brisinda; G Maria; A R Bentivoglio; F Cadeddu; G Marniga; F Brandara; A Albanese
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

6.  Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.

Authors:  E David Crawford; Kathryn Hirst; John W Kusek; Robert F Donnell; Steven A Kaplan; Kevin T McVary; Lance A Mynderse; Claus G Roehrborn; Christopher P Smith; Reginald Bruskewitz
Journal:  J Urol       Date:  2011-07-24       Impact factor: 7.450

7.  M3 subtype of muscarinic receptors mediate Ca2+ release from intracellular stores in rat prostate neuroendocrine cells.

Authors:  Jin Kyoung Kim; Soo Jung Kim; Ji Eun Lee; Kyeong Min Min; Sung Joon Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

8.  Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells.

Authors:  Stephanie Thebault; Morad Roudbaraki; Vadim Sydorenko; Yaroslav Shuba; Loic Lemonnier; Christian Slomianny; Etienne Dewailly; Jean-Louis Bonnal; Brigitte Mauroy; Roman Skryma; Natalia Prevarskaya
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 9.  Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders.

Authors:  H Henry Lai; Christopher P Smith
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

10.  Effect of Onabotulinum Toxin A on Substance P and Receptor Neurokinin 1 in the Rat Ventral Prostate.

Authors:  Omer Onur Cakir; Carol A Podlasek; Douglas Wood; Kevin E McKenna; Kevin T McVary
Journal:  Andrology (Los Angel)       Date:  2015-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.